8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K

                 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                                December 15, 2004
                Date of Report (Date of earliest event reported)


                         COMPETITIVE TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)

         Delaware                     1-8696                     36-2664428
(State or other jurisdiction        (Commission               (I.R.S. Employer
      of incorporation)             File Number)             Identification No.)

                 1960 Bronson Road, Fairfield, Connecticut 06824
               (Address of principal executive offices) (Zip Code)

                                 (203) 255-6044
              (Registrant's telephone number, including area code)

                               __________________
                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)


     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

|_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================


Item 8.01 Other Events.

     On December 16, 2004, Competitive Technologies, Inc. ("CTT") announced that
a license had been granted to Abbott Laboratories ("Abbott") under CTT's U.S.
Patent Number 4,940,658 for homocysteine assays. The granting of the license
settled previously filed litigation between CTT and Abbott.

     Pursuant to the license Abbott will pay a license fee and royalties on
sales of Abbott homocysteine assays. The license will relieve Abbott customers
from their obligation to pay royalties on results obtained using the Abbott
assay by virtue of the royalty paid by Abbott to CTT. CTT's share of the license
fee (that will be paid in January 2005) will be $5.2 million. The license also
releases Abbott's customers of any obligation to pay royalties to CTT for
homocysteine test results obtained using Abbott assays in the past, but does not
entitle them to any refund of any royalties previously paid to CTT.


A copy of the press release is attached as Exhibit 99.1.


Item 9.01. Financial Statements and Exhibits

      (c)  Exhibits.

Exhibit No.                Description
- -----------                -----------------------------------------------------

Exhibit 99.1               Press release dated December 16, 2004.


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                                  COMPETITIVE TECHNOLOGIES, INC.

Date: December 20, 2004                           By:    /s/ John B. Nano
                                                         ----------------
                                                         Name:  John B. Nano
                                                         Title: President and
                                                         Chief Executive Officer


                                  EXHIBIT INDEX

Exhibit No.        Description
- ------------       -------------------------------------------------------------

Exhibit 99.1       Press release dated December 16, 2004 announcing that CTT had
                   granted a license to Abbott Laboratories for homocysteine
                   assays.

EX-99.1

                                                                    Exhibit 99.1

                                                          For Immediate Release:


              COMPETITIVE TECHNOLOGIES LICENSES HOMOCYSTEINE PATENT
                                    TO ABBOTT

       Abbott Homocysteine Assays Carry Pass-Through License to Customers

Fairfield, CT and Abbott Park, IL (December 16, 2004) - Competitive
Technologies, Inc. (AMEX: CTT) and Abbott (NYSE: ABT) announced today that a
homocysteine patent license has been granted to Abbott under CTT's U.S. Patent
Number 4,940,658 and its foreign counterparts relating to homocysteine medical
tests.

Under terms of the agreement, Abbott is granted a license to the CTT technology
and will pay royalties on sales of Abbott homocysteine assays. Abbott's
homocysteine assay customers will be covered by the Abbott license from CTT.
Abbott customers such as hospital and commercial laboratories that have separate
homocysteine licenses from CTT will be relieved of their obligation to pay
royalties on reportable homocysteine results obtained using the Abbott assay by
virtue of the royalty paid by Abbott to CTT.

The agreement between CTT and Abbott includes a release to Abbott's customers of
any obligation to pay royalties to CTT for homocysteine test results obtained
using Abbott assays in the past. CTT has agreed not to pursue royalties from any
current or future Abbott customer with respect to past homocysteine assay tests
purchased from other diagnostic companies. CTT is pursuing such royalties
directly from the supplier diagnostic companies and reserves its rights against
these supplier diagnostics companies.

The license does not relieve Abbott customers for royalties on past or future
assays for methylmalonic acid. Customers should contact CTT for a license to
perform such assays.

The homocysteine patent is derived from discoveries made by CTT's clients, Drs.
Robert Allen and Sally Stabler from the University of Colorado and the late Dr.
John Lindenbaum from Columbia University.

About Abbott Laboratories

Abbott is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical products,
including nutritionals, devices and diagnostics. The company employs more than
55,000 people and markets its products in more than 130 countries. Abbott's news
releases and other information are available on the company's Web site at
www.abbott.com

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology
transfer and licensing provider focused on the technology needs of its customers
and transforming those requirements into commercially viable solutions. CTT is a
global leader in identifying, developing and commercializing innovative
technologies in life, digital, nano, and physical sciences developed by
universities, companies and inventors. The global market for technology transfer
services is estimated at $150 billion annually. CTT maximizes the value of
intellectual assets for the benefit of its customers, clients and shareholders.
Visit CTT's website: www.competitivetech.net


                                     (more)



Statements about our future expectations, including development and regulatory
plans, and all other statements in this document other than historical facts are
"forward-looking statements" within the meaning of applicable Federal Securities
Laws, and are not guarantees of future performance. These statements involve
risks and uncertainties inherent in our business, including those set forth in
Item 7 under the caption "Risk Factors," in our most recent Annual Report on
Form 10-K filed with the SEC on October 29, 2004, and other factors that may be
described in our other filings with the SEC, and are subject to change at any
time. Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement.

Direct inquiries to: Johnnie D. Johnson, Strategic IR, Inc.
                     Tel. (212) 754-6565; Fax (212) 754-4333

                     E-mail: jdjohnson@strategic-ir.com
                     E-mail: ctt@competitivetech.net

                                      (end)